Hyperfine (NASDAQ:HYPR) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Hyperfine (NASDAQ:HYPR) from a hold rating to a sell rating in a research report report published on Sunday,Wall Street Zen reports.

HYPR has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research report on Thursday, October 15th. Loop Capital set a $2.00 target price on shares of Hyperfine in a research report on Tuesday, October 27th. B. Riley Financial reissued a “buy” rating and set a $1.60 target price (down from $2.00) on shares of Hyperfine in a research note on Monday, August 10th. BTIG Research reissued a “buy” rating and set a $2.00 target price on shares of Hyperfine in a research note on Tuesday, September 22nd. Finally, Lucid Cap Mkts assumed coverage on shares of Hyperfine in a report on Tuesday, October 27th. They issued a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $2.02.

Hyperfine Stock Performance

NASDAQ HYPR opened at $0.72 on Friday. The stock has a market capitalization of $76.30 million, a P/E ratio of -1.89 and a beta of 1.50. The business has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $1.11. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.15 and a quick ratio of 5.45. Hyperfine has a one year low of $0.67 and a one year high of $1.94.

Hyperfine (NASDAQ:HYPR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.13 million. Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%. Research analysts expect that Hyperfine will post -0.34 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PFS Partners LLC increased its holdings in shares of Hyperfine by 150.0% during the third quarter. PFS Partners LLC now owns 50,000 shares of the company’s stock valued at $40,000 after acquiring an additional 30,000 shares in the last quarter. Walleye Capital LLC raised its position in shares of Hyperfine by 3.4% during the first quarter. Walleye Capital LLC now owns 223,988 shares of the company’s stock worth $242,000 after purchasing an additional 7,330 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Hyperfine during the second quarter worth approximately $419,000. Russell Investments Group Ltd. lifted its holdings in shares of Hyperfine by 7,695.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 487,994 shares of the company’s stock worth $394,000 after purchasing an additional 481,734 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Hyperfine by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 730,233 shares of the company’s stock worth $789,000 after purchasing an additional 365,490 shares in the last quarter. Institutional investors own 15.03% of the company’s stock.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside.